
The FDA approved adrabetadex for infantile-onset NPC based on a 55% lower risk of death vs external controls, with a boxed warning for hearing loss.
The AAP has just released updated guidelines on ADHD that include the recommendation for medication therapy for selected preschoolers (as young as 4 years old).
The AAP has just released






